Hon ANDREW LITTLE: The first shipment of Paxlovid has arrived in New Zealand ahead of schedule and will start being offered to those most at risk, from next week. The benefit of this medicine is that by protecting people from getting seriously ill, it will prevent the health system also from being overwhelmed. Regarding Evusheld, this is currently going through Medsafe approval and we expect New Zealanders who meet the criteria for it could receive treatment with it from about the middle of this year.